CHICAGO — A treatment that combines two different types of cancer-fighting medicines — Gilead Sciences’ Trodelvy with Merck’s Keytruda — reduced the risk of tumor progression by more than one-third in women with an aggressive form of breast cancer.
The results reported Saturday from the randomized Phase 3 study called ASCENT-04 could lead to a new treatment option for patients with newly diagnosed, metastatic, triple-negative breast cancer, experts said.
Gilead, which conducted the study, could also benefit from a boost in Trodelvy sales at a time when it faces competition from a similar drug made by AstraZeneca and Daiichi Sankyo.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
